Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022130531> ?p ?o ?g. }
- W2022130531 endingPage "109" @default.
- W2022130531 startingPage "100" @default.
- W2022130531 abstract "Despite optimal surgery and chemotherapy, the prognosis of ovarian cancer patients remains poor and new treatments are urgently needed. Solid tumors require the formation of new vessels for growth and metastasis. In the present study, we have used soluble vascular endothelial growth factor (sVEGF) receptors sVEGFR-1 and -3, soluble receptors Tie1 and Tie2 and their combinations in an ovarian cancer xenograft model. Human ovarian cancer cells were injected intraperitoneally into nude mice (n=42) and magnetic resonance imaging (MRI) was used for confirming tumors before gene delivery. Treatment with combined AdsVEGFR-1, AdsVEGFR-3 and AdsTie2 significantly decreased the size of the intraperitoneal tumors compared with the controls (AdLacZ; P=0.038) with significantly less microvessels and vascular area. Unexpectedly, treatment with combined AdsTie1 and AdsTie2 led to a dramatic shortening of the survival which was not observed in the groups receiving either of the soluble receptors alone (P=0.031). The only difference to other treatments was liver toxicity observed after the combined Tie receptor treatment. In conclusion, combined inhibition of VEGFR-1, VEGFR-3 and Tie2 pathways was safe and provided efficient therapy for ovarian cancer in mice." @default.
- W2022130531 created "2016-06-24" @default.
- W2022130531 creator A5004098265 @default.
- W2022130531 creator A5011777202 @default.
- W2022130531 creator A5014220812 @default.
- W2022130531 creator A5022247341 @default.
- W2022130531 creator A5023660858 @default.
- W2022130531 creator A5023824240 @default.
- W2022130531 creator A5040856325 @default.
- W2022130531 creator A5057253233 @default.
- W2022130531 creator A5065702208 @default.
- W2022130531 creator A5089509707 @default.
- W2022130531 date "2010-09-24" @default.
- W2022130531 modified "2023-10-17" @default.
- W2022130531 title "Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice" @default.
- W2022130531 cites W1489873347 @default.
- W2022130531 cites W1527522386 @default.
- W2022130531 cites W1573363574 @default.
- W2022130531 cites W1783580437 @default.
- W2022130531 cites W1964187194 @default.
- W2022130531 cites W1970614272 @default.
- W2022130531 cites W1982486040 @default.
- W2022130531 cites W1984674737 @default.
- W2022130531 cites W1992101966 @default.
- W2022130531 cites W1996430165 @default.
- W2022130531 cites W1996526210 @default.
- W2022130531 cites W1998258610 @default.
- W2022130531 cites W1998485988 @default.
- W2022130531 cites W2000292756 @default.
- W2022130531 cites W2000630426 @default.
- W2022130531 cites W2001282311 @default.
- W2022130531 cites W2003450086 @default.
- W2022130531 cites W2007742308 @default.
- W2022130531 cites W2013692456 @default.
- W2022130531 cites W2015600314 @default.
- W2022130531 cites W2022439153 @default.
- W2022130531 cites W2025933554 @default.
- W2022130531 cites W2026038921 @default.
- W2022130531 cites W2041895882 @default.
- W2022130531 cites W2048306047 @default.
- W2022130531 cites W2058680827 @default.
- W2022130531 cites W2059108446 @default.
- W2022130531 cites W2066888615 @default.
- W2022130531 cites W2068499444 @default.
- W2022130531 cites W2071068908 @default.
- W2022130531 cites W2091774189 @default.
- W2022130531 cites W2121547206 @default.
- W2022130531 cites W2125150769 @default.
- W2022130531 cites W2138934635 @default.
- W2022130531 cites W2140459348 @default.
- W2022130531 cites W2152215024 @default.
- W2022130531 cites W2155797787 @default.
- W2022130531 cites W2158743409 @default.
- W2022130531 cites W2161051751 @default.
- W2022130531 cites W2163301034 @default.
- W2022130531 cites W4251118184 @default.
- W2022130531 cites W4382916220 @default.
- W2022130531 doi "https://doi.org/10.1038/cgt.2010.56" @default.
- W2022130531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20865022" @default.
- W2022130531 hasPublicationYear "2010" @default.
- W2022130531 type Work @default.
- W2022130531 sameAs 2022130531 @default.
- W2022130531 citedByCount "15" @default.
- W2022130531 countsByYear W20221305312012 @default.
- W2022130531 countsByYear W20221305312013 @default.
- W2022130531 countsByYear W20221305312014 @default.
- W2022130531 countsByYear W20221305312015 @default.
- W2022130531 countsByYear W20221305312017 @default.
- W2022130531 countsByYear W20221305312022 @default.
- W2022130531 countsByYear W20221305312023 @default.
- W2022130531 crossrefType "journal-article" @default.
- W2022130531 hasAuthorship W2022130531A5004098265 @default.
- W2022130531 hasAuthorship W2022130531A5011777202 @default.
- W2022130531 hasAuthorship W2022130531A5014220812 @default.
- W2022130531 hasAuthorship W2022130531A5022247341 @default.
- W2022130531 hasAuthorship W2022130531A5023660858 @default.
- W2022130531 hasAuthorship W2022130531A5023824240 @default.
- W2022130531 hasAuthorship W2022130531A5040856325 @default.
- W2022130531 hasAuthorship W2022130531A5057253233 @default.
- W2022130531 hasAuthorship W2022130531A5065702208 @default.
- W2022130531 hasAuthorship W2022130531A5089509707 @default.
- W2022130531 hasBestOaLocation W20221305311 @default.
- W2022130531 hasConcept C121608353 @default.
- W2022130531 hasConcept C126322002 @default.
- W2022130531 hasConcept C134018914 @default.
- W2022130531 hasConcept C142724271 @default.
- W2022130531 hasConcept C167734588 @default.
- W2022130531 hasConcept C170493617 @default.
- W2022130531 hasConcept C2776694085 @default.
- W2022130531 hasConcept C2777025900 @default.
- W2022130531 hasConcept C2779013556 @default.
- W2022130531 hasConcept C2779094623 @default.
- W2022130531 hasConcept C2780394083 @default.
- W2022130531 hasConcept C2780427987 @default.
- W2022130531 hasConcept C502942594 @default.
- W2022130531 hasConcept C71924100 @default.
- W2022130531 hasConcept C85219853 @default.
- W2022130531 hasConceptScore W2022130531C121608353 @default.